GPP
VKTX icon

Great Point Partners’s Viking Therapeutics VKTX Stock Holding History

Great Point Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-598,550
Closed -$9.7M – 53
2023
Q2 		$9.7M Sell
598,550
-401,450
-40% -$8.41M 1.9% 20
2023
Q1 		$16.6M Sell
1,000,000
-295,034
-23% -$3.05M 3.27% 15
2022
Q4 		$12.2M Buy
+1,295,034
New +$5.78M 2.39% 17

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Great Point Partners's VKTX Position: Q3 2023 in Review

Great Point Partners sold out of Viking Therapeutics (VKTX) in Q3 2023, closing a stake of 598,550 shares — an estimated $9.7M sold.

Great Point Partners first reported a position in VKTX in Q4 2022 and held it in 3 quarters. The position peaked at $16.6M in Q1 2023. 179 funds tracked by Wall St. Rank hold VKTX as of Q3 2023.

  • Great Point Partners reported no remaining Viking Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Great Point Partners sold 598,550 Viking Therapeutics shares in Q3 2023, an estimated $9.7M.
  • Great Point Partners first reported a position in Viking Therapeutics in Q4 2022 and held it in 3 quarters.
  • Great Point Partners's Viking Therapeutics position peaked at $16.6M in Q1 2023.
  • 179 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2023.

Based on Great Point Partners's 13F filing for Q3 2023, filed 14 Nov 2023.